aDepartment of Cardiology, Daejeon St. Mary's Hospital bDepartment of Cardiology, Yeouido St. Mary's Hospital cDepartment of Cardiology, Uijeongbu St. Mary's Hospital dDepartment of Cardiology, Seoul St. Mary's Hospital eDepartment of Cardiology, Incheon St. Mary's Hospital fDepartment of Cardiology, St. Vincent's Hospital gDepartment of Cardiology, St. Paul's Hospital hDepartment of Cardiology, Bucheon St. Mary's Hospital, The Catholic University of Korea iDepartment of Pharmacology, PharmacoGenomics Research Center, College of Medicine jDepartment of Clinical Pharmacology, Busan Paik Hospital, Inje University, Busan, Korea.
Pharmacogenet Genomics. 2013 Oct;23(10):558-62. doi: 10.1097/FPC.0b013e328364eb92.
The impact of the CYP2C1917 polymorphism on the clinical outcome in Asians undergoing percutaneous coronary intervention (PCI) is unknown. We sought to assess the long-term impact of CYP2C1917 on the risk for adverse clinical events in 2188 Korean patients taking clopidogrel after PCI. The prevalence of the CYP2C19*17 allele [*wt/*17: 2.4% (n = 53), *17/*17: 0%] was very low. The 2-year cumulative event rates for bleeding [*wt/*17 vs. wt/wt: 2 vs. 2.3%; adjusted hazard ratio (HR), 1.23; 95% confidence interval (CI), 0.16-9.45], stent thrombosis (2 vs. 1.1%; HR, 3.98; 95% CI, 0.49-31.6) or composite of any death, and myocardial infarction or stroke (5.4 vs. 7.1%; HR, 1.37; 95% CI, 0.32-5.73) did not differ on the basis of the presence of CYP2C1917. In conclusion, in our study population of Asian patients, the CYP2C1917 polymorphism was not associated with adverse clinical outcomes after PCI because of its low prevalence, the rarity of homozygotes, and the relatively low rate of adverse clinical events.
CYP2C1917 多态性对亚洲经皮冠状动脉介入治疗（PCI）患者临床结局的影响尚不清楚。我们旨在评估 CYP2C1917 对 2188 例韩国 PCI 后服用氯吡格雷的患者不良临床事件风险的长期影响。CYP2C19*17 等位基因的流行率[*wt/*17：2.4%（n=53），*17/*17：0%]非常低。出血的 2 年累积事件发生率[wt/17 与wt/wt：2%与 2.3%；调整后的危险比（HR），1.23；95%置信区间（CI），0.16-9.45]、支架血栓形成（2%与 1.1%；HR，3.98；95%CI，0.49-31.6）或任何死亡、心肌梗死或卒中的复合终点（5.4%与 7.1%；HR，1.37；95%CI，0.32-5.73）均不取决于 CYP2C1917 的存在。总之，在我们的亚洲患者人群中，由于 CYP2C1917 多态性的低流行率、纯合子的罕见性以及不良临床事件的相对低发生率，该多态性与 PCI 后不良临床结局无关。
